Related Experiment Video
Updated: Jun 15, 2026

08:29
Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
14.8K
Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer
Parijatham S Thomas1,2, Anisha B Patel3, J Jack Lee4
1Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer Prevention Research (Philadelphia, Pa.)
|October 13, 2022
Abstract
Prevention Relevance:
Bexarotene is a rexinoid that has been shown to prevent mammary tumors in mouse models but oral dosing has toxicities. This phase I study evaluates topical bexarotene, as a potential chemoprevention agent, for safety and toxicity in high-risk women for breast cancer.

